Results 81 to 90 of about 30,645 (194)
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase [PDF]
Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients.
Hansen, B.E. (Bettina) +32 more
core +2 more sources
Artificial neural network accurately predicts hepatitis B surface antigen seroclearance.
Background & aimsHepatitis B surface antigen (HBsAg) seroclearance and seroconversion are regarded as favorable outcomes of chronic hepatitis B (CHB).
Ming-Hua Zheng +10 more
doaj +1 more source
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang +8 more
wiley +1 more source
ABSTRACT Background Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment‐naïve patients with CHD. This study analysed the pattern and determinants of ALT elevation in a large cohort of patients with CHD, including young adults, compared to propensity score‐matched (PSM) patients
Habiba Kamal +13 more
wiley +1 more source
HBV RNA AS A PREDICTOR OF HBEAG SEROCONVERSION IN PATIENTS WITH HEPATITIS B
Objective: To study the predictive value of serum hepatitis B virus pregenomic RNA (HBV pgRNA) in the seroconversion of HBeAg-positive chronic hepatitis B (CHB) patients. Methods: 135 patients with HBeAg positive CHB patients were admitted to our hospital from June 2021 to June 2022 were selected to detect the serum HBV pgRNA and HBV DNA levels with ...
Jun Tian +3 more
openaire +1 more source
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu +5 more
wiley +1 more source
ABSTRACT Background and Aim Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic‐associated steatotic liver disease (MASLD) poses new challenges.
Sheng‐Jie Shiue +12 more
wiley +1 more source
Hepatitis B virus (HBV) infection, a global public health problem can be asymptomatic, acute or chronic and can lead to serious consequences of infection, including cirrhosis, and hepatocellular carcinoma.
Anna Kramvis +3 more
doaj +1 more source
Abbreviations: e SC+: positive HBeAg seroconversion, eSC-: negative HBeAg seroconversion, WT: nodal width, dWT: The nodal size change for nodal width between acute flare stage and recovery stage.*p-value is from Pearson’s chi-square test.The power of ...
Kun-Ming Chung (523221) +9 more
core +1 more source
The aims of this study were to compare chronic hepatitis B (CHB) patients with genotypes B and C for the probability of HBeAg seroconversion, hepatitis activity, and viral replication before and after HBeAg seroconversion and to compare the prevalence of
Kato, T +11 more
core +1 more source

